[1] Chalasani N, Bonkovsky HL, Fontana R, et al. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN prospective study. Gastroenterology, 2015, 148: 1340-1352 e1347.
[2] Andrade RJ, Lucena MI, Kaplowitz N, et al. Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry. Hepatology, 2006, 44: 1581-1588.
[3] Aithal PG, Day CP. The natural history of histologically proved drug induced liver disease. Gut, 1999, 44: 731-735.
[4] Bjornsson E, Kalaitzakis E, Av Klinteberg V, et al. Long-term follow-up of patients with mild to moderate drug-induced liver injury. Aliment Pharmacol Ther, 2007, 26: 79-85.
[5] Fontana RJ, Hayashi PH, Gu J, et al. Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. Gastroenterology, 2014, 147: 96-108 e104.
[6] Medina-Caliz I, Robles-Diaz M, Garcia-Munoz B, et al. Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury. J Hepatol, 2016, 65: 532-542.
[7] Stine JG, Chalasani N. Chronic liver injury induced by drugs: a systematic review. Liver Int, 2015, 35: 2343-2353.
[8] Arranto AJ, Sotaniemi EA. Histologic follow-up of alpha-methyldopa-induced liver injury. Scand J Gastroenterol, 1981, 16: 865-872.
[9] Stine JG, Lewis JH. Hepatotoxicity of antibiotics: a review and update for the clinician. Clin Liver Dis, 2013, 17: 609-642, ix.
[10] Russo MW, Hoofnagle JH, Gu J, et al. Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. Hepatology, 2014, 60: 679-686.
[11] Forbes GM, Jeffrey GP, Shilkin KB, et al. Carbamazepine hepatotoxicity: another cause of the vanishing bile duct syndrome. Gastroenterology, 1992, 102: 1385-1388.
[12] Juricic D, Hrstic I, Radic D, et al. Vanishing bile duct syndrome associated with azithromycin in a 62-year-old man. Basic Clin Pharmacol Toxicol, 2010, 106: 62-65.
[13] Gendre G, Buclin T, Morard I, et al. Terbinafine induced hepatitis with persistent cholestasis. Rev Med Suisse, 2008, 4: 736-739.
[14] Perveze Z, Johnson MW, Rubin RA, et al. Terbinafine-induced hepatic failure requiring liver transplantation. Liver Transpl, 2007, 13: 162-164.
[15] Amacher DE, Chalasani N. Drug-induced hepatic steatosis. Semin Liver Dis, 2014, 34: 205-214.
[16] Fromenty B, Pessayre D. Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol Ther, 1995, 67: 101-154.
[17] Weinstein GD, Cox JW, Suringa DW, et al. Evaluation of possible chronic hepatotoxicity from methotrexate for psoriasis. Arch Dermatol, 1970, 102: 613-618.
[18] Zachariae H, Kragballe K, Sogaard H. Methotrexate induced liver cirrhosis. Studies including serial liver biopsies during continued treatment. Br J Dermatol, 1980, 102: 407-412.
[19] Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol, 2014, 109: 950-966; quiz 967.
[20] Kleiner DE. Histopathological challenges in suspected drug-induced liver injury. Liver Int, 2018, 38: 198-209.
[21] Chalasani N, Bjornsson E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology, 2010, 138: 2246-2259.
[22] Barge S, Ziol M, Nault JC. Autoimmune-like chronic hepatitis induced by olmesartan. Hepatology, 2017, 66: 2086-2088.
[23] Urban TJ, Shen Y, Stolz A, et al. Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenet Genomics, 2012, 22: 784-795.
[24] Ju C, Uetrecht JP. Mechanism of idiosyncratic drug reactions: reactive metabolite formation, protein binding and the regulation of the immune system. Curr Drug Metab, 2002, 3: 367-377.
[25] Kelly BD, Heneghan MA, Bennani F, et al. Nitrofurantoin-induced hepatotoxicity mediated by CD8+ T cells. Am J Gastroenterol, 1998, 93: 819-821.
[26] Norcross MA, Luo S, Lu L, et al. Abacavir induces loading of novel self-peptides into HLA-B*57: 01: an autoimmune model for HLA-associated drug hypersensitivity. AIDS, 2012, 26: F21-29.
[27] Czaja AJ. Transitioning from Idiopathic to Explainable Autoimmune Hepatitis. Dig Dis Sci, 2015, 60: 2881-2900.
[28] Kubes P, Mehal WZ. Sterile inflammation in the liver. Gastroenterology, 2012, 143: 1158-1172.
[29] Aithal GP, Ramsay L, Daly AK, et al. Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology, 2004, 39: 1430-1440.
[30] Suzuki A, Brunt EM, Kleiner DE, et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology, 2011, 54: 931-939.
[31] Heurgue-Berlot A, Bernard-Chabert B, Diebold MD, et al. Drug-induced autoimmune-like hepatitis: a case of chronic course after drug withdrawal. Dig Dis Sci, 2011, 56: 2504-2505.
[32] Czaja AJ. Drug-induced autoimmune-like hepatitis. Dig Dis Sci, 2011, 56: 958-976.
[33] Sebode M, Schulz L, Lohse AW. "Autoimmune(-Like)" drug and herb induced liver injury: new insights into molecular pathogenesis. Int J Mol Sci, 2017, 18. doi:10.3390/ijms18091954.
[34] Xiao X, Chang C. Diagnosis and classification of drug-induced autoimmunity (DIA). J Autoimmun, 2014, 48-49: 66-72. |
